san

Hexaware Announces Collaboration with San Francisco Unicorns to Boost Fan EngagementHexaware Announces Collaboration with San Francisco Unicorns to Boost Fan Engagement

Hexaware Announces Collaboration with San Francisco Unicorns to Boost Fan Engagement

Tech Solutions Provider Becomes Official Partner for the Bay Area's Team Through the 2026 Major League Cricket Season LONDON, March…

3 weeks ago
Bay Area Therapy Center Offers Specialized Therapy for Overcoming Communication and Relationship Issues in San FranciscoBay Area Therapy Center Offers Specialized Therapy for Overcoming Communication and Relationship Issues in San Francisco

Bay Area Therapy Center Offers Specialized Therapy for Overcoming Communication and Relationship Issues in San Francisco

SAN FRANCISCO, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Therapy Center is excited to announce an enhanced focus on…

1 month ago
Rising from the Ashes: Ivy En Rose MedSpa Reopens in San Francisco, Exemplifying Strength and Community SpiritRising from the Ashes: Ivy En Rose MedSpa Reopens in San Francisco, Exemplifying Strength and Community Spirit

Rising from the Ashes: Ivy En Rose MedSpa Reopens in San Francisco, Exemplifying Strength and Community Spirit

SAN FRANCISCO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- In a remarkable display of resilience and determination, Ivy En Rose MedSpa…

2 months ago
Asian Art Museum of San Francisco Appoints Dr. Soyoung Lee as Director and CEOAsian Art Museum of San Francisco Appoints Dr. Soyoung Lee as Director and CEO

Asian Art Museum of San Francisco Appoints Dr. Soyoung Lee as Director and CEO

An Esteemed Arts Executive and Trailblazing Asian Art Scholar, Lee will Serve as the Institution's Next Barbara Bass Bakar Director and…

2 months ago
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer SymposiumCelcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival (OS) among patients with HR+, HER2- advanced breast…

4 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

4 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

4 months ago
Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC.Updated results of…

4 months ago
San Francisco’s Black Hammer Brewing Announces Major Expansion, Opens Investment Opportunity to PublicSan Francisco’s Black Hammer Brewing Announces Major Expansion, Opens Investment Opportunity to Public

San Francisco’s Black Hammer Brewing Announces Major Expansion, Opens Investment Opportunity to Public

San Francisco, CA , Nov. 22, 2024 (GLOBE NEWSWIRE) -- Black Hammer Brewing, San Francisco's innovative craft brewery known for…

4 months ago
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer SymposiumOnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

November 01, 2024 17:30 ET | Source: OnKure Therapeutics, Inc. OnKure to host a conference call to review key data…

5 months ago